Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB6411 in Advanced Lung Cancer
NCT07367529Phase 2Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Feb 2026
- Primary completion
- Dec 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of TQB6411 in lung cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Feb 2026; status: recruiting.
02
Drugs
TQB6411
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT07367529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07367529.